Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

QIAGEN Reports Results for Third Quarter and First Nine Months of 2016

QIAGEN N.V.
Posted on: 02 Nov 16

PR Newswire

VENLO, the Netherlands, November 2, 2016

VENLO, the Netherlands, November 2, 2016 /PRNewswire/ --

  • QIAGEN records strong third quarter with accelerating 2016 performance : 
    • Q3 2016: Net sales of $338.7 million (+8% actual, +9% constant exchange rates, CER); EPS of $0.14; adjusted EPS of $0.29 ($0.29 CER) 
    • Free cash flowin first nine months of 2016up 15% to $187 million  
  • Molecular Diagnostics and Life Sciences customer classes deliver strong performance as Sample to Insight portfolio t ransformation builds momentum 
  • I nitiative s advancing to adjust cost base after period of investments, goal to sustain faster sales momentum while delivering margin gains  
  • QIAGEN on track to achieve 6-7% CER sales growth for 2016 and adjusted EPS target before restructuring costs ; initial sales and adjusted EPS outlook for 2017 
  • $250 million synthetic share repurchase set for completion in early 2017 as part of commitment to return $300 million by end of 2017 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2016, delivering on goals for higher net sales and adjusted earnings per share.

"We are pleased with the strong results for the third quarter, and the first nine months of 2016. These show QIAGEN's transformation is building momentum and a new sales growth trajectory is materializing. We are convinced these efforts to expand our leadership in molecular testing with a differentiated portfolio serving customers across the continuum from basic research to clinical healthcare will create significant value," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Click here for the full press release

A PDF version of the full press release including financial tables can be downloaded here

https://www.qiagen.com/us/about-us/press-releases/~/media/c830dc737a54427d89efb9c12e5c62ff.ashx

Contacts

Investor Relations:


John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen.com

Public Relations:

Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com

http://www.twitter.com/qiagen
http://www.facebook.com/QIAGEN
pr.qiagen.com

SOURCE QIAGEN N.V.

PR Newswire
www.prnewswire.com

Last updated on: 02/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.